Madrigal Pharmaceuticals Announces FDA Approval of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Moderate to Advanced Liver Fibrosi
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Citi Closes 30-Day Upside Catalyst Watch on Madrigal Pharmaceuticals (MDGL)
March 18, 2024 4:04 PM EDTCiti analyst David Lebowitz reiterated a Buy rating and $389.00 price target on Madrigal Pharmaceuticals (NASDAQ: MDGL).
The analyst comments "We are closing our Catalyst Watch for Madrigal following the approval of Rezdiffra (resmetirom) for the treatment of noncirrhotic nonalcoholic steatohepatitis (NASH, also known as metabolic... More
Madrigal Pharmaceuticals (MDGL) PT Raised to $425 at H.C. Wainwright, 'Rezdiffra Achieves Landmark Approval'
March 15, 2024 6:11 AM EDTH.C. Wainwright analyst Ed Acre raised the price target on Madrigal Pharmaceuticals (NASDAQ: MDGL) to $425.00 (from $405.00) while maintaining a Buy rating.
The analyst comments "Rezdiffra approved with a strong label that represents the "best case" for Madrigal's commercial opportunity. Yesterday, in a widely anticipated decision, Madrigal announced that the FDA has granted accelerated approval to Rezdiffra (resmetirom) as the first ever drug for MASH (formerly, NASH). We view the label as broad and highly supportive of the use of Rezdiffra as a foundational therapy in NASH patients with significant fibrosis. Specifically, the... More
Madrigal Pharmaceuticals (MDGL) PT Raised to $389 at Citi
March 15, 2024 3:49 AM EDTCiti analyst David Lebowitz raised the price target on Madrigal Pharmaceuticals (NASDAQ: MDGL) to $389.00 (from $382.00) while maintaining a Buy rating.
The analyst comments "Madrigal announced that Rezdiffra (Resmetirom) was approved as the first therapy to treat non-cirrhotic non-alcoholic steatohepatitis (NASH, also known as metabolic... More
